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INTRODUCTION
1Department of Internal Medicine, 2Division of Cardiology, Lehigh Valley Health Network, Allentown, Pennsylvania
Diastolic heart failure (dCHF) is a frequent diagnosis which can have many etiologies. The diagnosis is often attributed to 
hypertensive heart disease and further workup of the cause is disregarded. Systemic senile transthyretin amyloidosis, with a 
prevalence of 6-11 cases per million person-years, can often deposit in cardiac tissue. Cardiac amyloidosis (CA) associated 
with senile transthyretin deposition has been found in up to 13% of those with dCHF. However, many cases of dCHF caused by 
transthyretin related (TTR) CA may go undiagnosed.
DISCUSSION
•  Even though dCHF is a common cause of hospitalization, the initial 
differential for the cause of the heart failure must remain broad. The 
diagnosis of TTR-CA in patients with dCHF should be considered to 
avoid delay in optimizing treatment.
•  Patients with left ventricular concentric hypertrophy could be due to 
TTR-CA and could benefit from a more aggressive workup. 
•  This patient was able to benefit by starting the transplant evaluation 
process as well as avoiding typical heart failure medications which 
could potentially aggravate his condition.
•  As clinicians it is easy to be caught up in diagnosing and treating 
what is common and known. It is important to consider all possible 
etiologies to assist in coming to the correct diagnosis in a timely 
manner.
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CASE
A 64-year-old male presented to our ED with worsening dyspnea on exertion and weight gain.  His past medical history 
included NYHA stage 3, diastolic heart failure without coronary artery disease or a family history of heart failure, 
paroxysmal orthostatic tachycardia syndrome (POTS), carpal tunnel, asthma, and multiple antihypertensive medication 
intolerances.  He had already had five admissions over the last five years for exacerbations of dCHF.
A repeat ECHO demonstrated severe concentric left ventricular hypertrophy with global hypokinesis, an EF of 45% and 
elevated diastolic filling pressures.  Repeat ECG was notable for lower than expected voltage.  Given his progressively 
worsening concentric LVH, lower than expected voltage on ECG and progressively worsening LV function, infiltrative 
disease needed to be ruled out.  The patient underwent cardiac MRI (image 1) which confirmed severe concentric LV 
hypertrophy with late gadolinium enhancement within the LV myocardium suggesting infiltrative cardiomyopathy.  He 
was scheduled for a myocardial biopsy with congo red staining, and the diagnosis of cardiac amyloidosis (CA) was 
confirmed (image 2).   Due to the patient’s negative urinary and serum protein electrophoresis, a 99m Tc-pyrophosphate 
scintigraphy was performed to assess for TTR CA.  The scan confirmed the diagnosis with notable uptake within the 
LV myocardium consistent with TTR CA (image 3). Eventually, pathologic evaluation confirmed the diagnosis of TTR CA, 
and amino acid testing was negative for known TTR mutations suggesting the senile form of the TTR CA.  The patient is 
currently being evaluated for heart transplantation.
Image 1: Cardiac MR showing severe 
concentric left ventricular hypertrophy with 
late gadolinium enhancement.
Image 2: Congo Red stain of the amyloid deposition in the 
myocardium.
Image 3: 99m Tc-pyrophosphate scintigraphy with notable 
uptake in the myocardium of the left ventricle suggestive of 
TTR amyloidosis.
